Welcome to LookChem.com Sign In|Join Free
  • or
1-(4-fluorobenzyl)piperidin-4-amine(SALTDATA: 1.98HCl 0.75H2O) is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

92539-14-5

Post Buying Request

92539-14-5 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

92539-14-5 Usage

Uses

Used in Pharmaceutical Research:
1-(4-fluorobenzyl)piperidin-4-amine(SALTDATA: 1.98HCl 0.75H2O) is used as an intermediate in the synthesis of various pharmaceutical compounds for [application reason]. Its unique structure allows for the development of new drugs targeting specific receptors or enzymes in the body.
Used in Chemical Synthesis:
In the chemical industry, 1-(4-fluorobenzyl)piperidin-4-amine(SALTDATA: 1.98HCl 0.75H2O) is used as a building block for the creation of more complex molecules with potential applications in various fields, including materials science and specialty chemicals.
Used in Medicinal Chemistry:
1-(4-fluorobenzyl)piperidin-4-amine(SALTDATA: 1.98HCl 0.75H2O) serves as a key component in the design and development of novel therapeutic agents. Its fluoro-substituted benzyl group may impart specific pharmacological properties, making it a valuable asset in the search for new treatments for various diseases.

Check Digit Verification of cas no

The CAS Registry Mumber 92539-14-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,2,5,3 and 9 respectively; the second part has 2 digits, 1 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 92539-14:
(7*9)+(6*2)+(5*5)+(4*3)+(3*9)+(2*1)+(1*4)=145
145 % 10 = 5
So 92539-14-5 is a valid CAS Registry Number.

92539-14-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name 1-(4-Fluorobenzyl)piperidin-4-amine

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:92539-14-5 SDS

92539-14-5Relevant academic research and scientific papers

Design and development of novel thiazole-sulfonamide derivatives as a protective agent against diabetic cataract in Wistar rats via inhibition of aldose reductase

Yin, Liang,Zhang, Mingxue,He, Tiangeng

, p. 63 - 70 (2021/10/01)

In recent years, ALR2 (aldose reductase) inhibitors have attracted attention for their effective ability to reduce the progression of diabetes-associated cataracts. Therefore, in the present article, we intended to develop novel thiazole-sulfonamide hybrids as a potent inhibitor of ALR2. These molecules significantly inhibited the ALR2 level in the rat lenses homogenate, where the most potent compound 7b showed activity comparable to sorbinil as standard. In Wistar rats, compound 7b improved the insulin level and body weight of the experimental animal together with a reduction in the glucose output. Compound 7b showed a significant reduction in the expression of ALR2 in rat lenses in western blot analysis.

Substituted 2-thioxothiazolidin-4-one derivatives showed protective effects against diabetic cataract via inhibition of aldose reductase

Huang, Wanrong,Zhang, Yue,Liang, Xu,Yang, Lichun

, (2020/04/07)

In an effort to develop a new class of potent aldose reductase inhibitors against diabetic cataracts, a series of novel 2-thioxothiazolidine-4-one derivatives was synthesized in excellent yields via a facile synthetic route. These compounds were tested against aldehyde (ALR1) and aldose reductase (ALR2) enzymes, where they showed considerable inhibitory activity. Among the tested derivatives, compound 6e showed selective and excellent inhibition of ALR2 over ALR1. The experimental diabetes was induced by the intraperitoneal administration of streptozotocin in male Wistar rats. Compound 6e showed positive modulation of body weight, blood glucose, and blood insulin levels in diabetic rats. Compound 6e also showed ALR2 inhibition as evidenced by Western blot analysis in lens homogenates of Wistar rats having cataract. The docking study of 6e was also performed inside the active site of ALR2 to enumerate the key contacts for inhibitory activity.

N-substituted piperidine amide derivative and application thereof

-

, (2020/04/17)

The invention discloses an N-substituted piperidine amide derivative and application thereof and particularly relates to a series of novel N-substituted piperidine amide derivatives and medicine compositions comprising same. The compounds can be used as a

Piperidinyl Ureas Chemically Control Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation

Hammill, Jared T.,Scott, Daniel C.,Min, Jaeki,Connelly, Michele C.,Holbrook, Gloria,Zhu, Fangyi,Matheny, Amy,Yang, Lei,Singh, Bhuvanesh,Schulman, Brenda A.,Guy, R. Kiplin

, p. 2680 - 2693 (2018/04/23)

We previously discovered and validated a class of piperidinyl ureas that regulate defective in cullin neddylation 1 (DCN1)-dependent neddylation of cullins. Here, we report preliminary structure-activity relationship studies aimed at advancing our high-throughput screen hit into a tractable tool compound for dissecting the effects of acute DCN1-UBE2M inhibition on the NEDD8/cullin pathway. Structure-enabled optimization led to a 100-fold increase in biochemical potency and modestly increased solubility and permeability as compared to our initial hit. The optimized compounds inhibit the DCN1-UBE2M protein-protein interaction in our TR-FRET binding assay and inhibit cullin neddylation in our pulse-chase NEDD8 transfer assay. The optimized compounds bind to DCN1 and selectively reduce steady-state levels of neddylated CUL1 and CUL3 in a squamous cell carcinoma cell line. Ultimately, we anticipate that these studies will identify early lead compounds for clinical development for the treatment of lung squamous cell carcinomas and other cancers.

Rational Design and Multibiological Profiling of Novel Donepezil-Trolox Hybrids against Alzheimer's Disease, with Cholinergic, Antioxidant, Neuroprotective, and Cognition Enhancing Properties

Cai, Pei,Fang, Si-Qiang,Yang, Xue-Lian,Wu, Jia-Jia,Liu, Qiao-Hong,Hong, Hao,Wang, Xiao-Bing,Kong, Ling-Yi

, p. 2496 - 2511 (2017/11/21)

A novel series of donepezil-trolox hybrids were designed, synthesized, and evaluated as multifunctional ligands against Alzheimer's disease (AD). Biological assays showed that these derivatives possessed moderate to good inhibitory activities against acetylcholinesterase (AChE) and monoamine oxidase B (MAO-B) as well as remarkable antioxidant effects. The optimal compound 6d exhibited balanced functions with good inhibition against hAChE (IC50 = 0.54 μM) and hMAO-B (IC50 = 4.3 μM), significant antioxidant activity (41.33 μM IC50 by DPPH method, 1.72 and 1.79 trolox equivalent by ABTS and ORAC methods), excellent copper chelation, and Aβ1-42 aggregation inhibition effect. Furthermore, cellular tests indicated that 6d has very low toxicity and is capable of combating oxidative toxin (H2O2, rotenone, and oligomycin-A) induced neurotoxicity. Most importantly, oral administration of 6d demonstrated notable improvements on cognition and spatial memory against scopolamine-induced acute memory deficit as well as d-galactose (d-gal) and AlCl3 induced chronic oxidative stress in a mouse model without acute toxicity and hepatotoxicity. In summary, both in vitro and in vivo results suggested that 6d is a valuable candidate for the development of a safe and effective anti-Alzheimer's drug.

Design and development of a novel chalcone derivative as an anticholinesterase inhibitor for possible treatment of dementia

Zhao, Fu-Chun,Wu, Yan,Song, Xiao-Jie

, p. 3311 - 3317 (2017/07/17)

Background: Cognitive decline (e.g., memory loss), which mainly occurs in the elderly, is termed dementia. In the present study, we intended to explore the cholinesterase inhibitory activity of some novel synthesized chalcones, together with their effect on β-amyloid anti-aggregation. Material/Methods: A novel class of chalcone derivatives have been synthesized and characterized by FT-IR,1H-NMR,13C-NMR, and mass and elemental analysis. These derivatives were later used for the determination of acetylcholinesterase (AChE) inhibitory and β-amyloid anti-aggregation activity. Results: The results of the study showed that among the developed compounds, 8g inhibits AChE more prominently than BuChE, as suggested by a selectivity index (SI) of 2.88. Furthermore, the most potent compound, 8g, showed considerable action in inhibition of β-secretase and Aβ aggregation, but not as prominent as that of curcumin as a standard. Conclusions: In conclusion, our study revealed a novel class of chalcone derivatives as a selective inhibitor of AChE with considerably action against β-secretase and Aβ aggregation. Our results may be useful in developing AD drug therapy and warrant further investigation to generate more advanced analogues.

Synthesis, radiolabelling, and biodistribution studies of triazole derivatives for targeting melanoma

Rathmann, Stephanie M.,Janzen, Nancy,Valliant, John F.

, p. 773 - 780 (2016/11/09)

Molecular probes that target specific markers expressed in solid tumours are in demand for cancer imaging and radionuclide therapy applications. The synthesis, characterization, and in vivo evaluation of radioiodinated triazoles designed as probes to targ

2-PHENYL-3H-IMIDAZO[4,5-B]PYRIDINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY

-

Page/Page column 81, (2016/09/22)

A compound of formula (I′) or (I′′) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders associated with such activity.

Synthesis and studies on anticonvulsant and antibacterial activities of 1-Alkyl-4-(4H-1,2,4-triazol-4-yl)piperidine derivatives

Yuan, Yan-Ping,Wang, Shi-Ben,Gong, Guo-Hua,Quan, Zhe-Shan

, p. 1070 - 1078 (2015/04/14)

Two series of 1-Alkyl-4-(4H-1,2,4-triazol-4-yl)piperidines and 1-Alkyl-4-(2H-1,2,4-triazol-3-one-4-yl) piperidines were synthesized and their anticonvulsant and antibacterial activities were evaluated. Pharmacological tests showed that three of the synthesized compounds (6c, 6k, 7m) displayed 100% protection at a dose of 100 mg/kg. 4-(1-Octylpiperidin-4-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one (6c) was the most active compound in this study, with an ED50 of 65.4 mg/kg and a TD50 value of 241.2 mg/kg, resulting in a PI of 3.6. Four of the synthesized compounds showed potent inhibitory activity against gram positive bacteria staphylococcus aureus (RN4220, KCTC 209 and KCTC 503), especially against the strains of multidrug-resistant clinical isolates (MRSA3167/3506 and QRSA3505/3519). Among which compound 1-tetradeyl-4-(4H-1,2,4-triazol-4-yl)piperidine (7f) showed the most potent levels of activity (MIC = 2 ug/mL) against the gram-positive strains.

Design, synthesis, and biological evaluation of new diaminoquinazolines as β-catenin/Tcf4 pathway inhibitors

Mao, Yongjun,Lin, Nan,Tian, Wang,Han, Xiaofeng,Han, Xiaobing,Huang, Ziwei,An, Jing

, p. 1346 - 1359 (2012/04/04)

More than 50 new diaminoquinazoline derivatives have been synthesized and evaluated in a colon carcinoma cell growth inhibition assay using HCT116 and SW480 cells. Twenty compounds with good cell growth inhibitory activities (50 values 50 values of 1.5-2.5 μM for HCT116 cells with the luciferase reporter assay.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 92539-14-5
  • ©2008 LookChem.com,License:ICP NO.:Zhejiang16009103 complaints:service@lookchem.com
  • [Hangzhou]86-0571-87562588,87562578,87562573 Our Legal adviser: Lawyer